Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases - Poll - MDSpire

Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases

  • By

  • Fabien Boux

  • Alexis Mercier

  • Daniela Talba

  • Jean-Yves Giraud

  • Sandrine Dufort

  • Khalide Seddik

  • Sylvie Grand

  • Mélanie Gataleta

  • Alexandre Leboucher

  • Johan Pietras

  • Olivier De Beaumont

  • Géraldine Le Duc

  • Camille Verry

  • April 4, 2026

  • 0 min

Share

Original Source(s)

Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases

  • by Fabien Boux, Alexis Mercier, Daniela Talba, Jean-Yves Giraud, Sandrine Dufort, Khalide Seddik, Sylvie Grand, Mélanie Gataleta, Alexandre Leboucher, Johan Pietras, Olivier De Beaumont, Géraldine Le Duc, Camille Verry

  • April 4, 2026

Related Content

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report